A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV

September 10, 2026 updated by: ViiV Healthcare

A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV

The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV). This study will be conducted following the availability of initial safety and PK clinical data from formulation of the parent drug VH4524184.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

160

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
  • Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Exclusion Criteria:

  • History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
  • Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Previous exposure to the parent molecule VH4524184.
  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
  • Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Current enrolment or participation in another clinical study.
  • Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
  • Positive HIV antibody/antigen test.
  • History of clinically relevant hepatitis within the last 6 months.
  • Positive hepatitis B or hepatitis C test.
  • Clinically significant cardiovascular disease..
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
  • Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
  • Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.

The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
Participants will receive VH5356136 Formulation 1 on Day 1.
Placebo Comparator: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
Experimental: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
Participants will receive VH5356136 Formulation 2 on Day 1.
Placebo Comparator: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with drug-related adverse events (AEs)
Time Frame: From Day 1 to Month 18
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
From Day 1 to Month 18
Number of participants with Grade 2 to Grade 5 AEs
Time Frame: From Day 1 to Month 18
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
From Day 1 to Month 18
Number of participants with serious adverse events (SAEs)
Time Frame: From Day 1 to Month 18
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
From Day 1 to Month 18
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
AUC(0-tlast) for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Maximum plasma concentration (Cmax) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Cmax for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Tmax for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Terminal half-life (t1/2) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
t1/2 for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
From Day 1 (pre-dose) up to Month 18 post-dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 6, 2026

Primary Completion (Estimated)

May 9, 2029

Study Completion (Estimated)

May 9, 2029

Study Registration Dates

First Submitted

September 10, 2026

First Submitted That Met QC Criteria

September 10, 2026

First Posted (Actual)

September 16, 2026

Study Record Updates

Last Update Posted (Actual)

September 16, 2026

Last Update Submitted That Met QC Criteria

September 10, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 300862

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.